Fujitani, Kazumasa http://orcid.org/0000-0003-4954-5047
Shitara, Kohei
Takashima, Atsuo
Koeda, Keisuke
Hara, Hiroki
Nakayama, Norisuke
Hironaka, Shuichi
Nishikawa, Kazuhiro
Kimura, Yutaka
Amagai, Kenji
Hosaka, Hisashi
Komatsu, Yoshito
Shimada, Ken
Kawabata, Ryohei
Ohdan, Hideki
Kodera, Yasuhiro
Nakamura, Masato
Nakajima, Takako Eguchi
Miyata, Yoshinori
Moriwaki, Toshikazu
Kusumoto, Tetsuya
Nishikawa, Kazuo
Ogata, Kazuhiro
Shimura, Masashi
Morita, Satoshi
Koizumi, Wasaburo
Funding for this research was provided by:
Taiho Pharmaceutical
Article History
Received: 12 June 2020
Accepted: 7 October 2020
First Online: 2 November 2020
Change Date: 23 February 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10120-020-01144-7
Compliance with ethical standards
:
: Kazumasa Fujitani reports personal fees from Taiho, Lilly, Bristol-Myers Squibb, Ono and Yakult, outside the submitted work. Kohei Shitara reports grants and personal fees from Astellas, Lilly, Ono, Taiho and Merck, personal fees from Bristol-Myers Squibb, Takeda, Pfizer, Novartis, AbbVie, Yakult and GlaxoSmithKline, grants from Sumitomo Dainippon, Daiichi Sankyo, Chugai and Mediscience, outside the submitted work. Atsuo Takashima reports grants from Taiho, during the conduct of the study; grants from Sumitomo Dainippon, MSD, Ono, Mediscience and Bristol-Myers Squibb, outside the submitted work. Hiroki Hara reports grants from AstraZeneca, Sumitomo Dainippon, Merck Biopharma, Eisai, LSK BioPharma, Incyte, Pfizer, Boehringer-Ingelheim, Beigene and Astellas, grants and personal fees from Daiichi Sankyo, MSD, Taiho, Chugai, Ono and Bristol-Myers Squibb, personal fees from Lilly, Yakult, Sanofi, Takeda and Kyowa Hakko Kirin, outside the submitted work. Shuichi Hironaka reports personal fees from Taiho and Bristol-Myers Squibb, during the conduct of the study; personal fees from Sanofi, Tsumura, Yakult, Daiichi Sankyo, Lilly, Chugai, Nihon Kayaku and Ono, outside the submitted work. Kazuhiro Nishikawa reports personal fees from Bristol-Myers Squibb, Chugai, EA Pharma, Lilly, Ono, Taiho and Yakult, outside the submitted work. Kenji Amagai reports grants from MSD, Taiho, Nippon Zoki, Daiichi Sankyo and Hisamitsu, outside the submitted work. Hisashi Hosaka reports grants from Taiho, outside the submitted work. Yoshito Komatsu reports grants from A2 Healthcare, Sumitomo Dainippon, Eisai, EP-CRSU, EPS, Linical, NanoCarrier, QuintilesIMS, Sysmex, Astellas, Incyte, IQVIA and Syneos Health, grants and personal fees from Bayer, Daiichi Sankyo, Lilly, MSD, Taiho, Kyowa Kirin, Ono, Sanofi and Yakult, personal fees from Takeda, Bristol-Myers Squibb, Chugai, EA Pharma, Merck Biopharma, Nipro, Pfizer, Sawai, Shiseido, Asahi Kasei Pharma, Mitsubishi Tanabe, Merck Biopharma, Shire, Nippon Kayaku, Otsuka and Novartis, outside the submitted work. Ken Shimada reports grants and personal fees from Taiho and Chugai, during the conduct of the study. Yasuhiro Kodera reports grants from Nihon Kayaku, Kaken, EA Pharma, Novartis, KCI, Maruho, Daiichi Sankyo, Tsumura, Sawai, Bristol-Myers Squibb and Sanofi, grants and personal fees from Taiho, Chugai, Takeda, MSD, Yakult, Lilly, Ono, Covidien, Otsuka, personal fees from Johnson & Johnson, outside the submitted work. Masato Nakamura reports personal fees from Taiho, outside the submitted work. Takako Eguchi Nakajima reports personal fees from Mochida, Celltrion Healthcare, Merck, Sawai, Bayer, Bristol-Myers Squibb, Teijin Pharma, Pfizer, Novartis, Yakult and Nipro, grants and personal fees from Taiho, Chugai, Takeda, Sanofi, Daiichi Sankyo, Lilly, Nippon Kayaku, Ono and MSD, grants from Astellas, Sumitomo Dainippon, Eisai and Solasia Pharma, outside the submitted work. Yoshinori Miyata reports grants from Taiho, during the conduct of the study, grants from Taiho, outside the submitted work. Toshikazu Moriwaki reports grants from Taiho, during the conduct of the study, grants and personal fees from Taiho, Chugai, Takeda and Yakult, personal fees from Sanofi, Ono and Lilly, grants from Eisai, MSD, outside the submitted work. Kazuhiro Ogata reports employment at Taiho. Masashi Shimura reports non-financial support from Satoshi Morita, during the conduct of the study and employment at Taiho. Satoshi Morita reports personal fees from AstraZeneca, Bristol-Myers Squibb, Chugai, Lilly, MSD, Pfizer, Taiho and Ono, outside the submitted work. Keisuke Koeda, Norisuke Nakayama, Yutaka Kimura Ryohei Kawabata, Hideki Ohdan Tetsuya Kusumoto, Kazuo Nishikawa and Wasaburo Koizumi have nothing to disclose.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.
: Informed consent to be included in the study, or the equivalent, was obtained from all patients.